In addition, the study on the Intelligent Drug Discovery market for the forecast period, 2020 – 2027 quantifies the share occupied by the prominent players of the industry and enlightens the business owners from the fast-growing investment pockets and competitive landscape. Furthermore, the industry is classified into various segments with a detailed assessment of each and every aspect such as gross margin, profits, import and export status and others. All vital statistics are presented with the help of charts, tables and graphic images, which can be easily incorporated into any business presentation. The growing adoption of cloud-based applications and the expiration of patented drugs will pave the way for new generic and OTC medicines, which will influence market demand. The advancement in deep learning and machine learning will allow pharmaceutical companies to reorganize molecule binding properties with high accuracy.

The global Intelligent Drug Discovery Market is forecasted to be worth USD 3,711.8 Million by 2027, according to a current analysis by Emergen Research. The intelligent drug technology market is growing, and several pharmaceutical companies are focusing on the development of drugs using artificial intelligence. The pharma companies are taking advantage of the technology to discover drugs for more complex diseases.

Read more@https://www.emergenresearch.com/industry-report/intelligent-drug-di...

Key Highlights From The Report

In October 2020, Optibrium launched Cerella, an intelligence platform for active learning in drug discovery. Cerella’s architecture combines cloud computing with on-premises deployment offering both scalability and data security.

The software segment held a larger market share, and factors such as less cost and time, low rate of failure, a large number of software developers for the discovery of drugs, and strong demand from big pharmaceuticals are driving the segment’s demand.

Machine learning help in optimizing therapy by integrating clinical and biomedical data with computational models. It is used to build software for combinational therapies and testing drugs. Machine learning offers a lucrative potential for drug discovery and personalized medicine.

The growing incidence of oncology and the potential to affect several facets of cancer therapy will affect the demand for the market. The convergence of cancer therapy and AI has resulted in multiple solutions that address complex challenges. Intelligent platforms can accelerate the drug discovery process.

AI in medical imaging is witnessing lucrative growth in the Asia Pacific region due to a rise in R&D activities and development in the biotechnology and pharmaceutical sectors. Moreover, the presence of a significant patient pool will fuel the demand for better healthcare services, which will drive the demand for the market.

Key participants include IBM Corporation, Microsoft Corporation, Google, NVIDIA Corporation, Cloud Pharmaceuticals, Inc., Atomwise, Inc., Insilico Medicine, Exscientia, Bioage, and Envisagenics, among others.

Request For Free Sample@ https://www.emergenresearch.com/request-sample/356